Close Menu

NEW YORK – Interpace Biosciences reported after the close of the market on Wednesday that its 2019 fourth quarter revenues fell 29 percent year over year.

For the three months ended Dec. 31, 2019, the Parsippany, New Jersey-based firm's revenues fell to $4.1 million from $5.8 million in the same period the year before and missed the analysts' average estimate of $10.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.